Skip to content


Asarina Pharma CEO Peter Nordkild will present the company’s positive results from its Phase IIa study of Sepranolone for Tourette Syndrome at events in May and June 2023 in Europe and the US. See the schedule here.

May 19:  Assoc. Prof. Marco Bortolato (Dept Pharmacology & Toxicology, University of Utah) presents Asarina Pharma’s Phase IIa results at  TicCon – the Virtual National Conference of the Tourette Association of America, at 9.30 PM CET. His presentation is titled: ‘Putative  novel pharmacological treatments for tic disorders’. Register here:

June 5-8: CEO and Business Development Officer Otto Skolling attend BIO 2023, Boston International Convention Center, Boston Mass. US. Register here:

June 7-9: CEO Peter Nordkild presents the full  Phase IIa data at EESTS, the 15th European Conference on Tourette Syndrome and Tic Disorders in Brussels Belgium. Register for the event here:

Follow us on our social media channels as we post on each event. 

Tourette Syndrome

Watch our CEO Peter Nordkild explain the positive results of our Phase IIa study in Tourette Syndrome, at the RedEye Investor Forum in Gothenburg April 20, 2023 .

phase iia tourette syndrome results

Watch CEO Peter Nordkild discuss Asarina’s positive results with Direkt Studios, April 17, 2023 (interview begins 1 min 33 secs).

Explore our presentations Archive

REDEYE: Asarina Pharma: CEO Peter Nordkild presents at Investor Forum Online Feb 25th

direky stufoies

REDEYE: Asarina Pharma: Interview with CEO Peter Nordkild

REDEYE: Asarina Pharma: CEO Peter Norkild presents at Redeye Life Science Day 2020

REDEYE: Asarina Pharma: CEO Peter Nordkild presents at Neurology Seminar 2020

Press Kit

Access a range of resources on the Asarina Pharma team and offering.

The team

Management team
Scientific Advisory board

Company Logos

Image bank